Definium Therapeutics (NASDAQ:DFTX) CEO Robert Barrow Sells 19,023 Shares

Definium Therapeutics, Inc. (NASDAQ:DFTX) CEO Robert Barrow sold 19,023 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $37.94, for a total transaction of $721,732.62. Following the completion of the sale, the chief executive officer owned 1,494,640 shares of the company’s stock, valued at $56,706,641.60. This trade represents a 1.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Robert Barrow also recently made the following trade(s):

• On Thursday, June 25th, Robert Barrow sold 29,208 shares of Definium Therapeutics stock. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24.

Definium Therapeutics Trading Up 0.2%

Shares of Definium Therapeutics stock opened at $38.09 on Friday. Definium Therapeutics, Inc. has a 12-month low of $8.77 and a 12-month high of $49.70. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The stock has a market cap of $5.12 billion, a PE ratio of -11.10 and a beta of 2.23. The company has a 50-day moving average of $43.70 and a two-hundred day moving average of $29.49.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, research analysts anticipate that Definium Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Leerink Partners set a $52.00 price objective on shares of Definium Therapeutics and gave the company an “outperform” rating in a research note on Monday, June 22nd. Stifel Nicolaus upped their price target on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. JonesTrading increased their price target on shares of Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Wells Fargo & Company boosted their price objective on shares of Definium Therapeutics from $68.00 to $72.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Finally, Needham & Company LLC increased their target price on Definium Therapeutics from $50.00 to $66.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Definium Therapeutics has an average rating of “Buy” and an average price target of $63.00.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DFTX. Nykredit A S purchased a new stake in shares of Definium Therapeutics during the 2nd quarter valued at about $45,000. Russell Investments Group Ltd. grew its holdings in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Definium Therapeutics by 56.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after buying an additional 3,020 shares during the period. Caxton Associates LLP acquired a new position in Definium Therapeutics in the 3rd quarter worth $126,000. Finally, AXQ Capital LP purchased a new position in Definium Therapeutics in the 2nd quarter valued at about $585,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.